Quantitative Seed Amplification Assay: A Proof-of-Principle Study

Amyloid fibrils of the protein alpha-synuclein (alpha S) have recently been identified as a biomarker for Parkinson's disease (PD). To detect the presence of these amyloid fibrils, seed amplification assays (SAAs) have been developed. SAAs allow for the detection of alpha S amyloid fibrils in biomatrices such as cerebral spinal fluid and are promising for PD diagnosis by providing a dichotomous (yes/no) response. The additional quantification of the number of alpha S amyloid fibrils may enable clinicians to evaluate and follow the disease progression and severity. Developing quantitative SAAs has been shown to be challenging. Here, we report on a proof-of-principle study on the quantification of alpha S fibrils in fibril-spiked model solutions of increasing compositional complexity including blood serum. We show that parameters derived from standard SAAs can be used for fibril quantification in these solutions. However, interactions between the monomeric alpha S reactant that is used for amplification and biomatrix components such as human serum albumin have to be taken into account. We demonstrate that quantification of fibrils is possible even down to the single fibril level in a model sample consisting of fibril-spiked diluted blood serum.

Automated summary

Amyloid fibrils of alpha-synuclein have been identified as a biomarker for Parkinson's disease. Seed amplification assays can detect the presence of these fibrils and have potential for PD diagnosis. Quantitative analysis of alpha-synuclein fibrils can provide insights into disease progression and severity.